MHC-E-Restricted CD8⁺ T Cells Target Hepatitis B Virus-Infected Human Hepatocytes.

ABSTRACT: Currently 247 million people are living with chronic hepatitis B virus infection (CHB), and the development of novel curative treatments is urgently needed. Immunotherapy is an attractive approach to treat CHB, yet therapeutic approaches to augment the endogenous hepatitis B virus (HBV)-specific T cell response in CHB patients have demonstrated little success. In this study, we show that strain 68-1 rhesus macaque (RM) CMV vaccine vectors expressing HBV Ags engender HBV-specific CD8⁺ T cells unconventionally restricted by MHC class II and the nonclassical MHC-E molecule in RM. Surface staining of human donor and RM primary hepatocytes (PH) ex vivo revealed the majority of PH expressed MHC-E but not MHC class II. HBV-specific, MHC-E-restricted CD8⁺ T cells from RM vaccinated with RM CMV vaccine vectors expressing HBV Ags recognized HBV-infected PH from both human donor and RM. These results provide proof-of-concept that MHC-E-restricted CD8⁺ T cells could be harnessed for the treatment of CHB, either through therapeutic vaccination or adoptive immunotherapy.

SUBMITTER: Burwitz BJ 

PROVIDER: S-EPMC8109620 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature